Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University of Alabama at Birmingham
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03679598CT.gov Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency | — | Completed | — | — | — |
NCT03636347CT.gov A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alpha 1-Antitrypsin Deficiency
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alvelestat (this asset) | University of Alabama at Birmingham | P2 | B · 62 |
| Alpha-1-Proteinase Inhibitor | Grifols Therapeutics LLC | P4 | A |
| .Alpha.-1 Protease Inhibitor | Grifols Therapeutics LLC | P4 | A |
| Normal Human Serum Albumin | Baxalta now part of Shire | P4 | BBB |
| Fazirsiran | Takeda | P3 | BB |
| 20-valent pneumococcal conjugate vaccine | University of Alabama at Birmingham | P4 | BB |
| Aro-Aat | Arrowhead Pharmaceuticals | P2 | BB |
| Raav1-Cb-Haat | Beacon Therapeutics | P2 | BB |
| Kamada-Api | Kamada, Ltd. | P2/3 | B |
+42 more in the Alpha 1-Antitrypsin Deficiency cohort
Other indications for Alvelestat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | — | P2 | B · 62 |
| Pulmonary Emphysema | — | P2 | B · 57 |
| Type 2 Diabetes Mellitus | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Alvelestat in Alpha 1-Antitrypsin Deficiency. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/alvelestat-alpha-1-antitrypsin-deficiency
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →